Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE trial: Talazoparib in advanced breast cancer selected by RECAP HRD test
2018-002914-10Phase 2Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in breast cancer, sponsored by Erasmus MC Cancer Institute. Primary endpoint: Progression-free survival rate at 4 months (PFS4). Started Jul 2019; status: active.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-002914-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002914-10.